Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entinostat window trial in early breast cancer
NCT03361800Phase 1Terminated
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Nov 2018
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of entinostat in breast cancer, sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoint: Decrease in Ki-67 mRNA following treatment with entinostat at 9 days. Started Nov 2018; status: terminated.
02
Drugs
entinostat
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03361800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03361800.